Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Antirheumatic Drugs, Disease-Modifying

Known as: Drugs, Disease-Modifying Antirheumatic, Disease-Modifying, Antirheumatic Second-Line Drugs, dmards 
A pharmaceutical agent that is categorized by its ability to alter the progression of autoimmune disease.
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Aging is related to a number of functional and morphological changes leading to progressive decline of the biological functions… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Review
2018
Review
2018
Importance Rheumatoid arthritis (RA) occurs in about 5 per 1000 people and can lead to severe joint damage and disability… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Review
2018
Review
2018
OBJECTIVE To update French Society for Rheumatology recommendations about the management in clinical practice of patients with… Expand
Review
2018
Review
2018
Baricitinib (Olumiant®) is an oral, targeted synthetic DMARD that inhibits JAK1 and JAK2, which are implicated in the… Expand
  • table 1
  • table 2
Review
2018
Review
2018
BACKGROUND The present review is part of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study… Expand
  • table 1
  • table 2
Review
2018
Review
2018
IMPORTANCE Rheumatic immune-related adverse events (irAEs) occur in approximately 10-20% of anti-programmed death 1 (anti-PD1… Expand
Review
2017
Review
2017
Intravenous (IV) and subcutaneous (SC) tocilizumab (RoActemra®), an IL-6 receptor antagonist, are approved (± methotrexate) in… Expand
  • table 1
  • table 2
  • table 3
Highly Cited
2008
Highly Cited
2008
Guidelines and recommendations developed and/or endorsed by the American College of Rheumatology (ACR) are intended to provide… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Highly Cited
2008
Highly Cited
2008
OBJECTIVE To examine the efficacy and safety of the humanized anti-interleukin-6 receptor antibody tocilizumab combined with… Expand
Highly Cited
2004
Highly Cited
2004
OBJECTIVE To evaluate the efficacy and safety of monotherapy with adalimumab in patients with RA for whom previous DMARD… Expand
  • table 1
  • figure 1
  • table 2
  • figure 3
  • figure 2